Your present location:Home/About us/News/Marketing/Sars-cov-2 Omicron variant may has strong tolerance to
current therapeutic antibodies

Sars-cov-2 Omicron variant may has strong tolerance to
current therapeutic antibodiesRelease date:2022-01-10

The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic


The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike-protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by Sotrovimab. Similarly, the Omicron spike evaded neutralization by antibodies from convalescent or BNT162b2-vaccinated individuals with 10- to 44-fold higher efficiency than the spike of the Delta variant. Neutralization of the Omicron spike by antibodies induced upon heterologous ChAdOx1/BNT162b2-vaccination or vaccination with three doses of BNT162b2 was more efficient, but the Omicron spike still evaded neutralization more efficiently than the Delta spike. These findings indicate that most therapeutic antibodies will be ineffective against the Omicron variant and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant.

For details, please visit

Magen is paying her effort to help the resistance of new virus and has devleoped a complete solution for virus nucleic acid extration, including DNA/RNA extraction kits, raw materials and automated extraction machines.

For details please visit:

Back to list